In this special edition of the View, Dr. Eagle summarizes the top science that will be presented at TCT 2023 from October 23rd to October 26th in San Francisco.

Dr. Eagle shares some of the trials that have captured attention, including: Four Year Outcomes from the Evolut Low Risk Trial, Five-Year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low Risk Randomized Trial, Less-Than One-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug Eluting Stent Implantation for Acute Coronary Syndrome, TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement, and Individual Patient Data Pooled Analysis of Endovascular Ultrasound Renal Denervation.

These trials hold significant promise for advancing the field of interventional cardiology. We look forward to learning the results of the trials being presented. 

There will be daily updates giving more details on these trials and more.

The ACC is providing coverage of the latest science being presented at TCT 2023 in San Francisco. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #TCT2023.